Blood cancer patients may get liver protection from common drug
NCT ID NCT07476885
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This real-world study looks at whether polyene phosphatidylcholine injection can prevent or treat drug-induced liver injury in adults with blood cancers like leukemia and lymphoma. Researchers will review medical records of 1,000 patients to see how well the drug works and if it is safe. The main focus is on liver enzyme improvement after one week of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
polyene phosphatidylcholine injection
What this could lead to
If successful, this could show that polyene phosphatidylcholine is a safe and effective option to protect the liver during chemotherapy for blood cancers.
What could go wrong
This is an observational study looking back at medical records, not a controlled trial, so results may be less reliable. It is also early-stage and may not prove the drug works better than other options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG INDUCED LIVER INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••